Multidisciplinary team meetings improve survival in patients with esophageal cancer
- PMID: 39119871
- PMCID: PMC11518921
- DOI: 10.1093/dote/doae061
Multidisciplinary team meetings improve survival in patients with esophageal cancer
Abstract
Multidisciplinary team meetings (MDTs) are recommended for patients with esophageal cancer. Improved staging, timeliness to surgery and better adherence to guidelines have been attributed to MDTs, but there are few studies published on the MDTs' effect on survival. All patients with esophageal cancer in Sweden between 2006 and 2018 were grouped according to whether they had been discussed at an MDT as part of their clinical pathway. Factors affecting group allocation were explored with multivariable logistic regression, and the impact of MDT on survival was studied with Cox-regression and the Kaplan-Meier estimator. Of 6837 included patients, 1338 patients (20%) were not discussed at an MDT. Advanced age (80-90 years; odds ratio [OR] 0.25, 0.16-0.42 (95% confidence interval)) and clinical stage IVb (OR 0.65, 0.43-0.98) decreased the probability of being presented at an MDT, whereas high education level (OR 1.31, 1.02-1.67), being married (OR 1.20, 1.01-1.43), squamous histology (OR 1.50, 1.22-1.84) and later year of diagnosis (OR 1.33, 1.29-1.37 per year) increased the probability of an MDT. In multivariable adjusted analysis, MDT discussion was associated with improved survival (hazard ratios 0.72, 0.66-0.78) and median survival increased from 4.5 to 10.7 months. MDTs were associated with improved survival for esophageal cancer patients. Elderly patients with advanced disease and poor socioeconomic status were less likely to be presented at an MDT, but had clear survival-benefits if they were discussed in a multidisciplinary setting.
Keywords: cancer; esophageal; survival.
© The Author(s) 2024. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus.
Figures


References
-
- Al-Batran S E, Homann N, Pauligk C et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393(10184): 1948–57. - PubMed
-
- Shapiro J, van LanschotJ J B, Hulshof M et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16(9): 1090–8. - PubMed
-
- Nationellt vårdprogram för matstrups och magsäckscancer [National guidelines for treatment of esophageal- and gastric cancer] (version 5.0) [Internet]. Regionala Cancercentrum i samverkan. 2024. https://kunskapsbanken.cancercentrum.se/globalassets/cancerdiagnoser/mat.... Accessed 2024-06-26.
-
- Freeman R K, Van Woerkom J M, Vyverberg A, Ascioti A J. The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with esophageal cancer. Ann Thorac Surg 2011; 92(4): 1239–43. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical